All In Biotech

Drug Trial Radar · NCT06635850

A Study of Mosliciguat in PH-ILD

A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

135

Actual

Start

Oct 29, 2024

Primary completion

May 26, 2026

Study completion Jan 2028

Sponsor

Lead sponsor
Pulmovant, Inc.Industry
Sponsor type
Industry
First posted
Oct 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Conditions

  • Pulmonary Hypertension
  • Interstitial Lung Disease
  • Lung Diseases
  • Vascular Diseases
  • Cardiovascular Diseases
  • Fibrosis

Interventions

  • MosliciguatDrug

    Dose level 1, 2, or 3 for inhalation

  • Dry Powder InhalerDevice

    Dry powder inhaler for mosliciguat or placebo delivery

  • PlaceboDrug

    Matching placebo for inhalation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Week 16 in Pulmonary Vascular Resistance (PVR)Time frame: Baseline, Week 16

Locations

85 sites in 20 countries. Site status is shown where the registry gives one.

  • Clinical Research Site

    Phoenix, Arizona

  • Clinical Research Site

    Los Angeles, California

  • Clinical Research Site

    Sacramento, California

  • Clinical Research Site

    Santa Barbara, California

  • Clinical Research Site

    Torrance, California

  • Clinical Research Site

    Washington D.C., District of Columbia

  • Clinical Research Site

    Celebration, Florida

  • Clinical Research Site

    Chicago, Illinois

  • Clinical Research Site

    Iowa City, Iowa

  • Clinical Research Site

    Kansas City, Kansas

  • Clinical Research Site

    Louisville, Kentucky

  • Clinical Research Site

    Boston, Massachusetts

  • Clinical Research Site

    Boston, Massachusetts

  • Clinical Research Site

    New York, New York

  • Clinical Research Site

    New York, New York

  • Clinical Research Site

    Durham, North Carolina

  • Clinical Research Site

    Greensboro, North Carolina

  • Clinical Research Site

    Cincinnati, Ohio

  • Clinical Research Site

    Bend, Oregon

  • Clinical Research Site

    Philadelphia, Pennsylvania

  • Clinical Research Site

    East Providence, Rhode Island

  • Clinical Research Site

    Charleston, South Carolina

  • Clinical Research Site

    Dallas, Texas

  • Clinical Research Site

    Houston, Texas

  • Clinical Research Site

    Salt Lake City, Utah

  • Clinical Research Site

    Santa Fe, Argentina

  • Clinical Research Site

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Clinical Research Site

    Sydney, New South Wales, Australia

  • Clinical Research Site

    Westmead, New South Wales, Australia

  • Clinical Research Site

    Auchenflower, Queensland, Australia

  • Clinical Research Site

    Brussels, Brussels Capital, Belgium

  • Clinical Research Site

    Leuven, Flanders, Belgium

  • Clinical Research Site

    São Paulo, Brazil

  • Clinical Research Site

    São Paulo, Brazil

  • Clinical Research Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Clinical Research Site

    Blumenau, Santa Catarina, Brazil

  • Clinical Research Site

    Calgary, Alberta, Canada

  • Clinical Research Site

    London, Ontario, Canada

  • Clinical Research Site

    Toronto, Ontario, Canada

  • Clinical Research Site

    Prague, Prague, Czechia

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.